TrialESMO open2022
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
K Hotta et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
37 papers cite it
this paperpooled ittrialcites it